Objectives: We previously conducted a prospective study of landiolol hydrochloride (INN landiolol), an ultrashort-acting β-blocker, and reported that it could prevent atrial fibrillation after cardiac surgery. This trial was performed to investigate the safety and efficacy of landiolol hydrochloride in patients with left ventricular dysfunction undergoing cardiac surgery.
Methods: Sixty patients with a preoperative left ventricular ejection fraction of less than 35% were randomly assigned to 2 groups before cardiac surgery and then received intravenous infusion with landiolol hydrochloride (landiolol group) or without landiolol (control group). The primary end point was occurrence of atrial fibrillation as much as 1 week postoperatively. The secondary end points were blood pressure, heart rate, intensive care unit and hospital stays, ventilation time, ejection fraction, biomarkers of ischemia, and brain natriuretic peptide.
Results: Atrial fibrillation occurred in 3 patients (10%) in the landiolol group versus 12 (40%) in the control group, and its frequency was significantly lower in the landiolol group (P = .002). During the early postoperative period, levels of brain natriuretic peptide and ischemic biomarkers were significantly lower in the landiolol group than the control group. The landiolol group also had a significantly shorter hospital stay (P = .019). Intravenous infusion was not discontinued for hypotension or bradycardia in either group.
Conclusions: Low-dose infusion of landiolol hydrochloride prevented atrial fibrillation after cardiac surgery in patients with cardiac dysfunction and was safe, with no effect on blood pressure. This intravenous β-blocker seems useful for perioperative management of cardiac surgical patients with left ventricular dysfunction.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jtcvs.2015.07.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of bolus injections of landiolol hydrochloride as premedication in coronary artery CT angiography.
Insights Imaging
January 2025
Institute of Radiology, LKH Graz II, Graz, Austria.
Purpose: To assess the efficacy of bolus injections of landiolol hydrochloride as premedication in coronary artery CT angiography (CCTA).
Methods: The study population consisted of 37 patients (17 female; median age, 56 years; IQR, 19 years; range, 19-88 years) who underwent CCTA after intravenous injection of landiolol hydrochloride due to a heart rate > 60 bpm. Landiolol hydrochloride was administered in a stepwise manner until a heart rate of ≤ 60 bpm was achieved or a maximum dose of 60 mg was reached after six injections.
Case report: Thyroid storm in a three-year-old girl presenting with febrile status epilepticus and hypoglycemia.
Front Pediatr
June 2023
Department of Pediatrics, Mie University Graduate School of Medicine, Tsu, Japan.
Thyroid storm, though extremely rare in toddlers, requires prompt diagnosis and treatment because it can be fatal if left untreated. However, thyroid storm is not often considered in the differential diagnosis of a febrile convulsion due to its rarity in children. Herein, we report the case of a 3-year-old girl with thyroid storm who presented with febrile status epilepticus.
View Article and Find Full Text PDF[Chemical Stability after Mixing Continuous Infusion Drugs Used to Treat Cardiogenic Shock].
Yakugaku Zasshi
November 2022
Department of Practical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University.
Article Synopsis
- Continuous infusion drugs for treating cardiogenic shock may cause stability issues when mixed and administered through the same route, as they can affect each other's concentrations over time.
- This study evaluated the chemical stability of a mixture containing noradrenaline, milrinone, dobutamine hydrochloride, and landiolol hydrochloride, using HPLC to measure their concentrations.
- Findings showed that noradrenaline, milrinone, and dobutamine hydrochloride maintained their concentrations well for 24 hours, while landiolol hydrochloride degraded to below 90% within the same timeframe, indicating it should be administered separately.
Heart rate control with landiolol hydrochloride in infants with ventricular dysfunction and pulmonary hypertension.
ESC Heart Fail
February 2023
Department of Neonatology and Pediatric Intensive Care Medicine, University Children's Hospital Bonn, Venusberg-Campus 1, D-53127, Bonn, Germany.
Aims: Sinus tachycardia potentially leads to a deterioration of cardiac function in critically ill infants. The ultrashort-acting beta-blocker landiolol hydrochloride is a new pharmacological option for a selective heart rate (HR) control in patients with sinus tachycardia and heart failure.
Methods And Results: This study was a monocentric retrospective medical chart review study at the University Children's Hospital Bonn (Germany) from 01 January 2018 until 30 June 2020.
Intravenous landiolol for the prevention of atrial fibrillation after aortic root, ascending aorta, and aortic arch surgery: A propensity score-matched analysis.
JTCVS Open
September 2022
Department of Anesthesiology and Intensive Care, Hiroshima Citizens Hospital, Hiroshima, Japan.
Objective: Postoperative atrial fibrillation (POAF) after cardiac surgery is associated with increased mortality. The efficacy of landiolol hydrochloride for POAF prevention after coronary artery bypass grafting procedure and valve surgery has been reported. However, little evidence is available on its role in POAF prevention after aortic root, ascending aorta, and aortic arch surgery.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!